{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:33:01Z","timestamp":1789831981077,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"MHLW","doi-asserted-by":"crossref","award":["JPMH20FC1023"],"award-info":[{"award-number":["JPMH20FC1023"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00535-022-01914-3","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:05:53Z","timestamp":1662480353000},"page":"902-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis"],"prefix":"10.1007","volume":"57","author":[{"given":"Toshihiko","family":"Arizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Tazuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Isayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Tsuyuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan PSC Study Group (JPSCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol. 2017;67:1298\u2013323.","journal-title":"J Hepatol"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MOG.0000000000000352","volume":"33","author":"AC Cheung","year":"2017","unstructured":"Cheung AC, Lazaridis KN, LaRusso NF, et al. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol. 2017;33:149\u201357.","journal-title":"Curr Opin Gastroenterol"},{"key":"1914_CR3","first-page":"CD004036","volume":"1","author":"V Giljaca","year":"2010","unstructured":"Giljaca V, Poropat G, Stimac D, et al. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2010;1:CD004036.","journal-title":"Cochrane Database Syst Rev"},{"key":"1914_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00004836-200110000-00013","volume":"33","author":"M Parkes","year":"2001","unstructured":"Parkes M, Booth JC, Pillai G, et al. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol. 2001;33:319\u201322.","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"1914_CR5","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jhep.2008.01.020","volume":"48","author":"TJ Weism\u00fcller","year":"2008","unstructured":"Weism\u00fcller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis\u2013aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48(Suppl 1):S38-57.","journal-title":"J Hepatol"},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1385\/CRIAI:28:2:093","volume":"28","author":"J Worthington","year":"2005","unstructured":"Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol. 2005;28:93\u2013103.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1914_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","volume":"13","author":"B Caron","year":"2019","unstructured":"Caron B, Peyrin-Biroulet L, Pariente B, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study. J Crohns Colitis. 2019;13:1239\u201347.","journal-title":"J Crohns Colitis"},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","volume":"18","author":"KD Lynch","year":"2020","unstructured":"Lynch KD, Chapman RW, Keshav S, et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:179-187.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","volume":"34","author":"CK Triantos","year":"2011","unstructured":"Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34:901\u201310.","journal-title":"Aliment Pharmacol Ther"},{"key":"1914_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","volume":"58","author":"S Al Mamari","year":"2013","unstructured":"Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58:329\u201334.","journal-title":"J Hepatol"},{"key":"1914_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","volume":"11","author":"L Lindstr\u00f6m","year":"2013","unstructured":"Lindstr\u00f6m L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11:841\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1914_CR12","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/apt.12979","volume":"40","author":"C Rupp","year":"2014","unstructured":"Rupp C, R\u00f6ssler A, Halibasic E, et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014;40:1292\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"key":"1914_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","volume":"43","author":"PP Stanich","year":"2011","unstructured":"Stanich PP, Bj\u00f6rnsson E, Gossard AA, et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43:309\u201313.","journal-title":"Dig Liver Dis"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356\u201378.","journal-title":"Gut"},{"key":"1914_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660\u201378.","journal-title":"Hepatology"},{"key":"1914_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME, American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646\u201359 (quiz 660).","journal-title":"Am J Gastroenterol"},{"key":"1914_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237\u201367.","journal-title":"J Hepatol"},{"key":"1914_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67:549\u201358.","journal-title":"J Hepatol"},{"key":"1914_CR19","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/hep.30479","volume":"69","author":"EC Goode","year":"2019","unstructured":"Goode EC, Clark AB, Mells GF, et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology. 2019;69:2120\u201335.","journal-title":"Hepatology"},{"key":"1914_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","volume":"70","author":"GM Hirschfield","year":"2019","unstructured":"Hirschfield GM, Chazouill\u00e8res O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019;70:483\u201393.","journal-title":"J Hepatol"},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","volume":"73","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol. 2020;73:94\u2013101.","journal-title":"J Hepatol"},{"key":"1914_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.30237","volume":"69","author":"AJ Muir","year":"2019","unstructured":"Muir AJ, Levy C, Janssen HLA, et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology. 2019;69:684\u201398.","journal-title":"Hepatology"},{"key":"1914_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788\u2013801.","journal-title":"Hepatology"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","volume":"53","author":"H Isayama","year":"2018","unstructured":"Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol. 2018;53:1006\u201334.","journal-title":"J Gastroenterol"},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jhbp.432","volume":"24","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Tazuma S, Nakazawa T, et al. No negative impact of serum IgG4 levels on clinical outcome in 435 patients with primary sclerosing cholangitis from Japan. J Hepato-Bil Pancreat Sci. 2017;24:217\u201325.","journal-title":"J Hepato-Bil Pancreat Sci"},{"key":"1914_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","volume":"21","author":"A Tanaka","year":"2014","unstructured":"Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepato-Bil Pancreat Sci. 2014;21:43\u201350.","journal-title":"J Hepato-Bil Pancreat Sci"},{"key":"1914_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.1840160315","volume":"16","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16:707\u201314.","journal-title":"Hepatology"},{"key":"1914_CR28","first-page":"1472","volume":"43","author":"N De Maria","year":"1996","unstructured":"De Maria N, Colantoni A, Rosenbloom E, et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology. 1996;43:1472\u20139.","journal-title":"Hepatogastroenterology"},{"key":"1914_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"KD Lindor","year":"1997","unstructured":"Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med. 1997;336:691\u20135.","journal-title":"N Engl J Med"},{"key":"1914_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808\u201314.","journal-title":"Hepatology"},{"key":"1914_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900\u20137.","journal-title":"Gastroenterology"},{"key":"1914_CR32","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464\u201372.","journal-title":"Gastroenterology"},{"key":"1914_CR33","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.29882","volume":"68","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen CY, Lindor KD, Mehta R, et al. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology. 2018;68:1174\u201388.","journal-title":"Hepatology"},{"key":"1914_CR34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","volume":"29","author":"HJ van Hoogstraten","year":"1998","unstructured":"van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol. 1998;29:417\u201323.","journal-title":"J Hepatol"},{"key":"1914_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11894-999-0085-4","volume":"1","author":"YM Lee","year":"1999","unstructured":"Lee YM, Kaplan MM. Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid. Curr Gastroenterol Rep. 1999;1:38\u201341.","journal-title":"Curr Gastroenterol Rep"},{"key":"1914_CR36","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931\u201341.","journal-title":"Hepatology"},{"key":"1914_CR37","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171\u201381.","journal-title":"N Engl J Med"},{"key":"1914_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","volume":"75","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021;75:565\u201371.","journal-title":"J Hepatol"},{"key":"1914_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jhbp.281","volume":"22","author":"S Mizuno","year":"2015","unstructured":"Mizuno S, Hirano K, Isayama H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepato-Bil Pancreat Sci. 2015;22:766\u201370.","journal-title":"J Hepato-Bil Pancreat Sci"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01914-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01914-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01914-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:09:30Z","timestamp":1666735770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01914-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01914-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT received consultant fees from EA Pharma, GlaxoSmithKline, and Gilead Sciences. Other authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}